BACKGROUND AND AIMS: We investigated PTEN expression in primary pancreatic cancer and pancreatic cancer liver metastasis in order to evaluate the interrelationship between PTEN expression and clinicopathological characteristics of pancreatic cancer patients with and without liver metastasis. METHODS: Eighty five primary pancreatic cancer specimens without liver metastasis were analyzed as controls. Eighty seven pancreatic cancer specimens and homologous liver metastasis specimens were investigated immunohistochemically, and the correlation between immunohistochemical findings and clinicopathological factors was investigated. RESULTS: A strong PTEN expression was observed in 52 (61.2%) specimens from patients without liver metastasis. In contrast, only 26 (29.9%) specimens were observed in patients with liver metastasis. A strong PTEN expression was apparently associated with low-grade lymph node metastasis (p <0.05) and TNM stage (p <0.05). PTEN expression in patients without liver metastasis was apparently stronger than that with liver metastasis. In addition, among patients with liver metastasis, the 5-year survival rate was markedly higher in patients with strong PTEN expression compared to those with weak PTEN expression. CONCLUSIONS: Our results suggest that a high level of PTEN expression is associated with low-grade liver metastasis and satisfactory patient survival in pancreatic cancer. The diagnostic evaluation of PTEN expression may provide valuable prognostic information to aid treatment strategies for pancreatic cancer patients.
BACKGROUND AND AIMS: We investigated PTEN expression in primary pancreatic cancer and pancreatic cancer liver metastasis in order to evaluate the interrelationship between PTEN expression and clinicopathological characteristics of pancreatic cancerpatients with and without liver metastasis. METHODS: Eighty five primary pancreatic cancer specimens without liver metastasis were analyzed as controls. Eighty seven pancreatic cancer specimens and homologous liver metastasis specimens were investigated immunohistochemically, and the correlation between immunohistochemical findings and clinicopathological factors was investigated. RESULTS: A strong PTEN expression was observed in 52 (61.2%) specimens from patients without liver metastasis. In contrast, only 26 (29.9%) specimens were observed in patients with liver metastasis. A strong PTEN expression was apparently associated with low-grade lymph node metastasis (p <0.05) and TNM stage (p <0.05). PTEN expression in patients without liver metastasis was apparently stronger than that with liver metastasis. In addition, among patients with liver metastasis, the 5-year survival rate was markedly higher in patients with strong PTEN expression compared to those with weak PTEN expression. CONCLUSIONS: Our results suggest that a high level of PTEN expression is associated with low-grade liver metastasis and satisfactory patient survival in pancreatic cancer. The diagnostic evaluation of PTEN expression may provide valuable prognostic information to aid treatment strategies for pancreatic cancerpatients.
Authors: Joanne W Chiu; Hilda Wong; Roland Leung; Roberta Pang; Tan-To Cheung; Sheung-Tat Fan; Ronnie Poon; Thomas Yau Journal: Oncologist Date: 2014-08-12
Authors: Wai Chin Foo; Asif Rashid; Hua Wang; Matthew H Katz; Jeffrey E Lee; Peter W Pisters; Robert A Wolff; James L Abbruzzese; Jason B Fleming; Huamin Wang Journal: Hum Pathol Date: 2012-12-20 Impact factor: 3.466
Authors: S Boeck; A Jung; R P Laubender; J Neumann; R Egg; C Goritschan; U Vehling-Kaiser; C Winkelmann; L Fischer von Weikersthal; M R Clemens; T C Gauler; A Märten; S Klein; G Kojouharoff; M Barner; M Geissler; T F Greten; U Mansmann; T Kirchner; V Heinemann Journal: Br J Cancer Date: 2012-11-20 Impact factor: 7.640